A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections

Susanna Esposito, Sonia Bianchini, Samantha Bosis, Claudia Tagliabue, Ilaria Coro, Alberto Argentiero, Nicola Principi, Susanna Esposito, Sonia Bianchini, Samantha Bosis, Claudia Tagliabue, Ilaria Coro, Alberto Argentiero, Nicola Principi

Abstract

Background: Over many years, OM-85, a lysate of 21 common bacterial respiratory pathogens, has been demonstrated to prevent respiratory recurrences in children. However, further studies are needed to explore the true importance of OM-85 in the prevention of respiratory tract infections (RTIs) in children. This study was planned to further contribute to the evaluation of the role played by OM-85 in prevention of recurrent RTIs in children.

Methods: This study was a randomized (3:3:1), placebo-controlled, double-blind, single-centre, phase IV trial carried out in Italy to assess the efficacy of OM-85 (Broncho-Vaxom®; Vifor Pharma; Meyrin 2/Geneva, Switzerland) in reducing the number of new RTI episodes in 288 children aged 1 to 6 years with a history of recurrent RTIs and to compare the efficacy of the standard 3-month regimen with that of administration of OM-85 for 6 months during a 6-month study period.

Results: The number of RTIs and of children who experienced at least one RTI were significantly lower among patients receiving OM-85 for 3 months than among those given placebo (33% vs 65.1%, p < 0.0001). Differences were statistically significant for upper RTIs (i.e., common cold/viral pharyngitis and acute otitis media; p < 0.0001 and p = 0.006, respectively). Days of absence from day-care for children and working days lost by parents were significantly lower in the group with children treated with OM-85 for 3 months than in the placebo group (p = 0.007 and p = 0.004, respectively). No difference was seen between children who received OM-85 for 3 and those who received OM-85 for 6 months. The prevalence of atopy as well as the history of recurrent wheezing and age of the study child did not influence the results. Benefit was maximally evident among children with a history of frequent recurrences. OM-85 was well tolerated and safe, even in children who received an influenza vaccination.

Conclusions: The use of OM-85 for 3 months in 3 series of 10 consecutive days each time reduces the risk of recurrent RTIs in children, with a favourable safety profile. The greater effect observed in children prone to several respiratory episodes than in non-prone children seems to indicate that this lysate should be administered especially to children with a proven high susceptibility to RTIs.

Keywords: Acute otitis media; Bacterial lysate; Common cold; OM-85; Recurrent respiratory tract infection.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Vuononvirta J, Mertsola J, et al. Burden of recurrent respiratory tract infections in children: a prospective cohort study. Pediatr Infect Dis J. 2016;35:e362–e369. doi: 10.1097/INF.0000000000001304.
    1. Schaad UB, Esposito S, Razi CH. Diagnosis and management of recurrent respiratory tract infections in children: a practical guide. Arch Pediatr Infect Dis. 2016;4:1–10.
    1. Principi N, Esposito S, Cavagna R, Bosis S, Droghetti R, Faelli N, et al. Recurrent respiratory tract infections in pediatric age: a population-based survey of the therapeutic role of macrolides. J Chemother. 2003;15:53–59. doi: 10.1179/joc.2003.15.1.53.
    1. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen KL, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;18:198–209. doi: 10.1097/ACI.0000000000000433.
    1. de Martino M, Ballotti S. The child with recurrent respiratory infections: normal or not? Pediatr Allergy Immunol. 2007;18(Suppl 18):13–18. doi: 10.1111/j.1399-3038.2007.00625.x.
    1. Principi N, Di Cara G, Bizzarri I, Isidori C, Borgia P, Mignini C, et al. Prevention of invasive pneumococcal disease: problems emerged after some years of the 13-valent pneumococcal conjugate vaccine use. Curr Infect Dis Rep. 2018;20:1a. doi: 10.1007/s11908-018-0607-z.
    1. Principi N, Esposito S. Protection of children against influenza: emerging problems. Hum Vaccin Immunother. 2018;14:750–757. doi: 10.1080/21645515.2017.1279772.
    1. Esposito S, Musio A. Immunostimulants and prevention of recurrent respiratory tract infections. J Biol Regul Homeost Agents. 2013;27:627–636.
    1. Esposito S, Bianchini S, Polinori I, Principi N. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: a retrospective study. Int J Environ Res Public Health. 2019;16. pii:E1065. doi: 10.3390/ijerph16061065.
    1. Kearney SC, Dziekiewicz M, Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol. 2015;114:364–369. doi: 10.1016/j.anai.2015.02.008.
    1. Bessler WG, Vor dem Esche U, Masihi N. The bacterial extract OM-85 BV. protects mice against influenza and salmonella infection. Int Immunopharmacol. 2010;10:1086–1090. doi: 10.1016/j.intimp.2010.06.009.
    1. Rossi GA, Bessler W, Ballarini S, Pasquali C. Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice. Ital J Pediatr. 2018;44:112. doi: 10.1186/s13052-018-0569-7.
    1. Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010;6:5–12. doi: 10.1007/s12519-010-0001-x.
    1. Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. doi: 10.1016/j.intimp.2017.10.032.
    1. Esposito S, Marchisio P, Prada E, Daleno C, Porretti L, Carsetti R, et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;32:2546–2552. doi: 10.1016/j.vaccine.2014.03.055.
    1. Cherry J, Demmler-Harrison G, Kaplan S, Steinbach W, Hotez P. Feigin and Cherry’s textbook of pediatric infectious diseases. 8. Atlanta: Elsevier; 2019.
    1. Schaad UB, Mütterlein R, Goffin H, BV-Child Study Group Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest. 2002;122:2042–2049. doi: 10.1378/chest.122.6.2042.
    1. Esposito S, Cohen R, Domingo JD, Pecurariu OF, Greenberg D, Heininger U, et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J. 2012;31:e78–e85. doi: 10.1097/INF.0b013e318255dc5b.
    1. Wark PAB, Ramsahai JM, Pathinayake P, Malik B, Bartlett NW. Respiratory viruses and asthma. Semin Respir Crit Care Med. 2018;39:45–55. doi: 10.1055/s-0037-1617412.
    1. Razi CH, Harmancı K, Abacı A, Özdemir O, Hızlı S, Renda R, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010;126:763–769. doi: 10.1016/j.jaci.2010.07.038.
    1. Jara-Pérez JV, Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clin Ther. 2000;22:748–759. doi: 10.1016/S0149-2918(00)90008-0.
    1. Shallcross LJ, Davies DS. Antibiotic overuse: a key driver of antimicrobial resistance. Br J Gen Pract. 2014;64:604–605. doi: 10.3399/bjgp14X682561.
    1. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6:e619–e629. doi: 10.1016/S2214-109X(18)30186-4.
    1. Bielicki JA, Lundin R, Sharland M, ARPEC Project Antibiotic resistance prevalence in routine bloodstream isolates from children’s hospitals varies substantially from adult surveillance data in Europe. Pediatr Infect Dis J. 2015;34:734–741. doi: 10.1097/INF.0000000000000652.
    1. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Mongen JJL. Immunostimulants for preventing respiratory tract infection in children. Evid Based Child Health. 2012;7:629–717. doi: 10.1002/ebch.1833.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren